EE298 Cost-Effectiveness of Brexucabtagene Autoleucel (Brexu-cel, CAR-T) for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma in Greece
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.545
https://www.valueinhealthjournal.com/article/S1098-3015(22)02749-8/fulltext
Title :
EE298 Cost-Effectiveness of Brexucabtagene Autoleucel (Brexu-cel, CAR-T) for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02749-8&doi=10.1016/j.jval.2022.09.545
First page :
Section Title :
Open access? :
No
Section Order :
10077